Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Summit Therapeutics Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 5.6× Summit Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Summit Therapeutics Inc for 16 Days on average.
| MDLZ | SMMT | |
|---|---|---|
Market Cap | $77.43B | $13.71B |
Volume | 7,695,104 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $26.38 |
52-Week Low | $51.51 | $12.43 |
Typical Hold Time | 107 Days | 16 Days |
Enterprise Value | $97.78B | $13.04B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.41, up 1.73% with a bullish technical signal. The company shows strong fundamentals with consistent earnings beats, $38.54B in 2025 revenue, and improving cash flow. Analyst consensus is strongly bullish with a $70.29 price target. Recent developments include a dividend increase to $0.52 and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling investment case with solid profitability (8.86% net margin), attractive valuation (P/E 22.22), and strong analyst support. Key risks include cocoa cost pressures and competitive threats. The stock offers upside potential to consensus targets while providing defensive characteristics in volatile markets.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
